United States Pharmaceuticals

Arbutus Biopharma Corp (ABUS)

Track

Track

Arbutus Biopharma Corp experienced multiple proposed and planned share divestments by directors and officers between February and April 2025. These transactions involved significant volumes of equity. The most recent activity occurred on April 21, 2025, when a board member initiated a proposed sale. No insider trading transactions have been recorded within the last three months.
Ticker: ABUS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Arbutus Biopharma Corp. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
McElhaugh Michael J. Director Non-Executive Director
Transaction date
Proposed sale
Price
486.45
Quantity 56,377
Value US$1,913,151
McElhaugh Michael J. Director Non-Executive Director
Transaction date
Proposed sale
Price
483.38
Quantity 33,055
Value US$2,538,860
1.4
Sofia Michael J. Officer Officer
Transaction date
Proposed sale
Price
184.64
Quantity 42,147
Value US$4,813,727
1.4
Sofia Michael J. Officer Officer
Transaction date
Proposed sale
Price
3.20
Quantity 150,000
Value US$480,000
1.4
Sofia Michael J. Officer Officer
Transaction date
Proposed sale
Price
3.38
Quantity 100,000
Value US$338,000
1.4
Sofia Michael J. Member of immediate family of any of the foregoing
Transaction date
Proposed sale
Price
3.29
Quantity 167,162
Value US$549,963
Naftzger J. Christopher General Counsel and CCO Officer
Transaction date
Planned sale
Price
3.28
Quantity 11,333 -11.6%
Value US$37,206
2.4
Sims Karen Chief Medical Officer Officer
Transaction date
Planned sale
Price
3.28
Quantity 19,348 -15.4%
Value US$63,519
McElhaugh Michael J. Interim President & CEO Executive Director
Transaction date
Planned sale
Price
3.28
Quantity 23,790 -1.6%
Value US$78,103
HASTINGS DAVID C Chief Financial Officer Officer
Transaction date
Planned sale
Price
3.28
Quantity 22,183 -12.2%
Value US$72,827
David C. Hastings Officer Officer
Transaction date
Proposed sale
Price
3.28
Quantity 22,183
Value US$72,827
2.4
Karen Sims Officer Officer
Transaction date
Proposed sale
Price
3.28
Quantity 19,348
Value US$63,519
Michael J. McElhaugh Director and Officer Executive Director
Transaction date
Proposed sale
Price
3.28
Quantity 23,790
Value US$78,103
2.0
MANCHESTER KEITH S Non-Executive Director
Transaction date
Sale
Price
3.69
Quantity 8,846 -16.1%
Value US$32,637
HASTINGS DAVID C Chief Financial Officer Officer
Transaction date
Planned sale
Price
2.31
Quantity 9,593 -5.0%
Value US$22,184
1.4
Sofia Michael J. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
2.31
Quantity 9,982 -0.7%
Value US$23,083
McElhaugh Michael J. Interim President & CEO Executive Director
Transaction date
Planned sale
Price
2.31
Quantity 10,164 -0.7%
Value US$23,504
2.4
Sims Karen Chief Medical Officer Officer
Transaction date
Planned sale
Price
2.31
Quantity 4,358 -3.4%
Value US$10,078
1.4
Sofia Michael J. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
5.09
Quantity 200,000 -13.3%
Value US$1,018,000
McElhaugh Michael J. Chief Business Officer Officer
Transaction date
Planned sale
Price
5.00
Quantity 20,000 -1.5%
Value US$100,000
McElhaugh Michael J. Chief Business Officer Officer
Transaction date
Planned sale
Price
5.00
Quantity 10,000 -0.7%
Value US$50,032
McElhaugh Michael J. Chief Business Officer Officer
Transaction date
Planned sale
Price
5.00
Quantity 30,000 -2.2%
Value US$150,000
McElhaugh Michael J. Chief Business Officer Officer
Transaction date
Planned sale
Price
5.01
Quantity 20,000 -1.4%
Value US$100,200
1.4
Sofia Michael J. Chief Scientific Officer Officer
Transaction date
Sale
Price
9.51
Quantity 4,250 -0.3%
Value US$40,436
1.4
Sofia Michael J. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
10.00
Quantity 10,000 -0.7%
Value US$100,000
1.4
Sofia Michael J. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
8.91
Quantity 10,000 -0.7%
Value US$89,060
1.4
Sofia Michael J. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
8.45
Quantity 10,000 -0.7%
Value US$84,500
1.4
Sofia Michael J. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
8.40
Quantity 10,000 -0.6%
Value US$84,000
1.4
Sofia Michael J. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
8.00
Quantity 10,000 -0.6%
Value US$80,000
1.4
Sofia Michael J. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
8.00
Quantity 10,000 -0.6%
Value US$80,000
1.4
Sofia Michael J. Chief Scientific Officer
Transaction date
Sale
Price
3.68
Quantity 20,000 -10.4%
Value US$73,500
1.4
Sofia Michael J. Chief Scientific Officer
Transaction date
Sale
Price
3.75
Quantity 10,000 -5.0%
Value US$37,500
1.7
HENRIQUES RICHARD C JR Non-Executive Director
Transaction date
Purchase
Price
6.95
Quantity 1,000 +inf%
Value US$6,950
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-04-21 2025-04-21 PrS Proposed sale
McElhaugh Michael J.

Director

Non-Executive Director
56,377
486.45
US$1,913,151 		56,377 486.45 US$1,913,151
2025-04-15 2025-04-15 PrS Proposed sale
McElhaugh Michael J.

Director

Non-Executive Director
33,055
483.38
US$2,538,860 		33,055 483.38 US$2,538,860
2025-03-24 2025-03-24 PrS Proposed sale
1.4
Sofia Michael J.

Officer

Officer
42,147
184.64
US$4,813,727 		42,147 184.64 US$4,813,727
2025-03-19 2025-03-19 PrS Proposed sale
1.4
Sofia Michael J.

Officer

Officer
150,000
3.20
US$480,000 		150,000 3.20 US$480,000
2025-03-13 2025-03-13 PrS Proposed sale
1.4
Sofia Michael J.

Officer

Officer
100,000
3.38
US$338,000 		100,000 3.38 US$338,000
2025-03-07 2025-03-07 PrS Proposed sale
1.4
Sofia Michael J.

Member of immediate family of any of the foregoing
167,162
3.29
US$549,963 		167,162 3.29 US$549,963
2025-02-05 2025-02-04 PlS Planned sale
Naftzger J. Christopher

General Counsel and CCO

Officer
11,333 -11.6%
3.28
US$37,206 		11,333 -11.6% 3.28 US$37,206
2025-02-05 2025-02-04 PlS Planned sale
2.4
Sims Karen

Chief Medical Officer

Officer
19,348 -15.4%
3.28
US$63,519 		19,348 -15.4% 3.28 US$63,519
2025-02-05 2025-02-04 PlS Planned sale
McElhaugh Michael J.

Interim President & CEO

Executive Director
23,790 -1.6%
3.28
US$78,103 		23,790 -1.6% 3.28 US$78,103
2025-02-05 2025-02-04 PlS Planned sale
HASTINGS DAVID C

Chief Financial Officer

Officer
22,183 -12.2%
3.28
US$72,827 		22,183 -12.2% 3.28 US$72,827
2025-02-04 2025-02-04 PrS Proposed sale
David C. Hastings

Officer

Officer
22,183
3.28
US$72,827 		22,183 3.28 US$72,827
2025-02-04 2025-02-04 PrS Proposed sale
2.4
Karen Sims

Officer

Officer
19,348
3.28
US$63,519 		19,348 3.28 US$63,519
2025-02-04 2025-02-04 PrS Proposed sale
Michael J. McElhaugh

Director and Officer

Executive Director
23,790
3.28
US$78,103 		23,790 3.28 US$78,103
2025-02-04 2025-02-04 PrS Proposed sale
J. Christopher Naftzger

Officer

Officer
11,333
3.28
US$37,206 		11,333 3.28 US$37,206
2024-08-16 2024-08-14 S Sale
2.0
MANCHESTER KEITH S
Non-Executive Director
8,846 -16.1%
3.69
US$32,637 		8,846 -16.1% 3.69 US$32,637
2024-02-05 2024-02-02 PlS Planned sale
HASTINGS DAVID C

Chief Financial Officer

Officer
9,593 -5.0%
2.31
US$22,184 		9,593 -5.0% 2.31 US$22,184
2024-02-05 2024-02-02 PlS Planned sale
1.4
Sofia Michael J.

Chief Scientific Officer

Officer
9,982 -0.7%
2.31
US$23,083 		9,982 -0.7% 2.31 US$23,083
2024-02-05 2024-02-02 PlS Planned sale
McElhaugh Michael J.

Interim President & CEO

Executive Director
10,164 -0.7%
2.31
US$23,504 		10,164 -0.7% 2.31 US$23,504
2024-02-05 2024-02-02 PlS Planned sale
2.4
Sims Karen

Chief Medical Officer

Officer
4,358 -3.4%
2.31
US$10,078 		4,358 -3.4% 2.31 US$10,078
2021-12-03 2021-12-01 PlS Planned sale
1.4
Sofia Michael J.

Chief Scientific Officer

Officer
200,000 -13.3%
5.09
US$1,018,000 		200,000 -13.3% 5.09 US$1,018,000
2021-02-10 2021-02-09 PlS Planned sale
McElhaugh Michael J.

Chief Business Officer

Officer
20,000 -1.5%
5.00
US$100,000 		20,000 -1.5% 5.00 US$100,000
2020-12-16 2020-12-14 PlS Planned sale
McElhaugh Michael J.

Chief Business Officer

Officer
10,000 -0.7%
5.00
US$50,032 		10,000 -0.7% 5.00 US$50,032
2020-12-16 2020-12-14 PlS Planned sale
McElhaugh Michael J.

Chief Business Officer

Officer
30,000 -2.2%
5.00
US$150,000 		30,000 -2.2% 5.00 US$150,000
2020-07-27 2020-07-23 PlS Planned sale
McElhaugh Michael J.

Chief Business Officer

Officer
20,000 -1.4%
5.01
US$100,200 		20,000 -1.4% 5.01 US$100,200
2018-08-14 2018-08-13 S Sale
1.4
Sofia Michael J.

Chief Scientific Officer

Officer
4,250 -0.3%
9.51
US$40,436 		4,250 -0.3% 9.51 US$40,436
2018-07-13 2018-07-11 PlS Planned sale
1.4
Sofia Michael J.

Chief Scientific Officer

Officer
10,000 -0.7%
10.00
US$100,000 		10,000 -0.7% 10.00 US$100,000
2018-07-10 2018-07-09 PlS Planned sale
1.4
Sofia Michael J.

Chief Scientific Officer

Officer
10,000 -0.7%
8.91
US$89,060 		10,000 -0.7% 8.91 US$89,060
2018-07-10 2018-07-06 PlS Planned sale
1.4
Sofia Michael J.

Chief Scientific Officer

Officer
10,000 -0.7%
8.45
US$84,500 		10,000 -0.7% 8.45 US$84,500
2018-07-06 2018-07-05 PlS Planned sale
1.4
Sofia Michael J.

Chief Scientific Officer

Officer
10,000 -0.6%
8.40
US$84,000 		10,000 -0.6% 8.40 US$84,000
2018-07-06 2018-07-03 PlS Planned sale
1.4
Sofia Michael J.

Chief Scientific Officer

Officer
10,000 -0.6%
8.00
US$80,000 		10,000 -0.6% 8.00 US$80,000
2017-10-05 2017-10-03 PlS Planned sale
1.4
Sofia Michael J.

Chief Scientific Officer

Officer
10,000 -0.6%
8.00
US$80,000 		10,000 -0.6% 8.00 US$80,000
2017-08-17 2017-08-15 S Sale
1.4
Sofia Michael J.

Chief Scientific Officer
20,000 -10.4%
3.68
US$73,500 		20,000 -10.4% 3.68 US$73,500
2017-08-17 2017-08-15 S Sale
1.4
Sofia Michael J.

Chief Scientific Officer
10,000 -5.0%
3.75
US$37,500 		10,000 -5.0% 3.75 US$37,500
2015-08-26 2015-08-24 B Purchase
1.7
HENRIQUES RICHARD C JR
Non-Executive Director
1,000 +inf%
6.95
US$6,950 		1,000 +inf% 6.95 US$6,950
Explore more

More insider trading research around Arbutus Biopharma Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America